![](https://investorshub.advfn.com/uicon/460265.png?cb=1488922170)
Monday, June 03, 2024 8:19:15 AM
Presentation Details:
Title: Protecting Patients by Removing Need for Lymphodepletion to Better Preserve Immune Function
Conference Track: Clinical Track
Date and Time: Wednesday, June 12, 2024, 12:00 pm ET
Dr. Song’s presentation will detail the Company’s novel allogeneic blood-derived NK cell therapy (“SNK02”) commercial manufacturing and cryopreservation process, as well provide an update on their initial Phase 1 results using SNK02 to treat patients with advanced refractory solid tumors. Furthermore, Dr. Song will explore the potential benefits of eliminating pre-treatment lymphodepletion in patients undergoing SNK02 therapy, aiming to safeguard immune function and aid in recovery. Avoiding lymphodepletion before administering cancer treatment can provide many benefits including reduced toxicity, preservation of immune function, and potentially enhancing treatment efficacy. The presentation will also include a discussion on an unexpected discovery from the SNK02 Phase 1 trial, hinting at its possible applicability as a treatment for patients beyond cancer.
Recent NKGN News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/22/2024 09:01:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 01:19:39 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 01:16:19 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 01:14:43 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 01:11:45 AM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 06:05:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 11:12:43 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 10:19:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 09:14:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/27/2023 09:02:04 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/27/2023 09:01:25 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 12/19/2023 06:41:42 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2023 09:39:00 PM
- NKGen Biotech Shares Rise 8% After FDA Clears IND Application for SNK01 • Dow Jones News • 10/24/2023 02:56:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2023 12:05:14 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM